Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07829471
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Clinical Outcomes
- Neoadjuvant Therapy
- Pancreatic Adenocarcinoma
- Symptom Monitoring
- ePRO
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Standard of Care — OTHERStandard of Care
Study Details
To learn if routine symptom monitoring using questionnaires during chemotherapy and/or radiation therapy in patients with PDAC improves patient health-related quality of life and experience with care.
Key Dates
- First listed
- Sep 21, 2026
- Start date
- Feb 21, 2027
- Status verified
- Sep 2026
- Primary completion
- Jul 1, 2030
- Completion
- Jul 1, 2032
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Post-Implementation CohortStandard Clinical Care + QW ePRO
- Experimental: Pre-Implementation CohortStandard Clinical Care
Primary Outcome Measure
safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]
Central Contacts
- Rebecca A Snyder, MD713-792-0036
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UT MD Anderson Cancer Center | Houston | Texas | 77044 | Rebecca A Snyder, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By condition
By specialty
By research site
Related Studies
- Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic AdenocarcinomaPHASE1 · Recruiting · Diakonos Oncology Corporation · Houston, Texas
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Bristol-Myers Squibb · Clovis, California